CSL Limited (ASX:CSL)
169.50
-1.71 (-1.00%)
Sep 10, 2026, 4:15 PM AEST
CSL Limited Revenue
In the fiscal year ending June 30, 2026, CSL Limited had annual revenue of $15.80B USD with 1.54% growth. CSL Limited had revenue of $7.47B in the half year ending June 30, 2026, with 10.64% growth.
Revenue
$15.80B
Revenue Growth
+1.54%
P/S Ratio
3.55
Revenue / Employee
$544.72K
Employees
29,000
Market Cap
81.18B AUD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 15.80B | 239.00M | 1.54% |
| Jun 30, 2025 | 15.56B | 758.00M | 5.12% |
| Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
| Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
| Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 1.29B |
| Mesoblast | 173.82M |
| Clinuvel Pharmaceuticals | 94.02M |
| BLS Pharmaceuticals | 73.91M |
| Neuren Pharmaceuticals | 69.53M |
| PYC Therapeutics | 25.99M |
| Actinogen Medical | 12.67M |
| Starpharma Holdings | 12.67M |
CSL Limited News
- 8 hours ago - CSL Ltd's Dividend Analysis - GuruFocus
- 9 days ago - Trump Administration Reaches Drug Pricing Deals With 9 Companies - WSJ
- 10 days ago - Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers - CNBC
- 10 days ago - Trump administration to announce drug pricing deals - Reuters
- 23 days ago - Full Year 2026 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 23 days ago - CSL Posts Loss In FY26 On Restructuring Costs, Impairments - Nasdaq
- 23 days ago - CSL Limited Earnings Call Transcript: H2 2026 - Transcripts
- 23 days ago - CSL Limited Slides: H2 2026 - Filings